Codex Genetics’s Annual Oncology Roundtable: Tackling Minimal Residual Disease and Complex Mutations

Codex Genetics shared a post on LinkedIn:

”Annual Oncology Roundtable: Tackling Minimal Residual Disease and Complex Mutations.

Thanks to all the amazing doctors who joined our Roundtable Dinner last Friday! The discussions were truly enlightening as we shared our latest endeavors in AI-powered Clinical Data Management and Comprehensive Genomic Profiling. We were honored to have Alexa Jen, Guardant Health AMEA Genomics Lead, present the groundbreaking results from the COSMOS-CRC-01 trial, which showcased an outstanding 90.7% recurrence-free survival rate at 24 months for Colorectal Cancer patients with a negative Guardant Reveal report after surgery.

With Guardant360’s tissue panel upgraded to encompass 498 genes and the liquid biopsy panel now covering 739 genes and methylation-based Tumor Fraction (i.e. a prognostic indicator), we embark together on an exciting journey of Comprehensive Genomic Profiling. The evening was filled with collaboration and innovation, and we are deeply grateful for the opportunity to bring together such a remarkable group of professionals.

Special thanks to Amy Chang, Alan Ka-Lun KAI, Conrad Lee, Kenny Ng and Louisa Lui for coming to our event!

Nakamura et al., ASCO GI 2024 Abstract#180. Allen Chi-Shing Y., Sherie Lee, Alisha C, Kristine Ning Hsu.

Read our new spec sheets here:
Guardant TissueNext (439-gene).
Guardant360 powered by Infinity (789-gene).”

Source: Codex Genetics/LinkedIn